Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8615
+0.0183 (2.17%)
May 6, 2026, 3:40 PM EDT - Market open
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$35,720
Profits / Employee
-$1,574,946
Market Cap
9.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| Genprex | 13 |
| Kiora Pharmaceuticals | 13 |
| NuCana | 12 |
| XTL Biopharmaceuticals | 10 |
| Creative Medical Technology Holdings | 4 |
| PharmaCyte Biotech | 2 |
APRE News
- 15 days ago - Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 5 weeks ago - Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - GlobeNewsWire
- 7 weeks ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 2 months ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire